TIDMRUA

RNS Number : 9059R

RUA Life Sciences PLC

03 July 2020

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Notice of Final Results

RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon(TM) ), announces that it expects to report its audited final results for the year ended 31 March 2020 on 13 July 2020.

For further information contact:

RUA Life Sciences

   Bill Brown, Chairman                                  Tel: +44 (0) 77 3071 8296

Shore Capital

   Tom Griffiths/David Coaten                       Tel: +44 (0)20 7408 4080

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon(TM) , the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon(TM) , manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Medical :      End-to-end contract developer and manufacturer 
                     of medical devices and implantable fabric specialist. 
 RUA Biomaterials   Licensor of Elast-Eon(TM) polymers to the medical 
  :                  device industry. 
 RUA Vascular:      Development of large bore polymer sealed grafts 
                     and soft tissue patches. 
 RUA Structural     Development of tri leaflet polymeric heart valves. 
  Heart :

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORFLFVEDFIFIII

(END) Dow Jones Newswires

July 03, 2020 02:00 ET (06:00 GMT)

Aortech (LSE:AOR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aortech Charts.
Aortech (LSE:AOR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aortech Charts.